; and (V) to encourage notification and consultation among parties as they are considering pharmaceutical manufacturing subsidies to increase coordination and avoid creating conditions such as oversupply or market inefficiencies among the parties. (v) With respect to government procurement— (I) to provide reciprocal access to government procurements for such products in parties to the agreement; (II) to increase coordination between participant countries and facilitate the involvement of participant countries’ companies in bids to supply such products; and (III) to ensure that any participant in the agreement that is not already so designated, becomes designated for purposes of section 301 of the Trade Agreements Act of 1979 ( 19 U.S.C. 2511 ). (vi) With respect to trade in services— (I) to obtain fair, open, and transparent access to supply chain services in the markets of parties to the agreement, such as distribution, logistics, and transportation services; (II) to ensure any restrictions or regulatory requirements maintained on such services are adopted and maintained in a transparent and efficient manner; and (III) to require parties to establish an internal process for identifying restrictions or regulatory requirements that could be waived in the event of a declared emergency. (vii) With respect to transparency and trade facilitation— (I) to obtain commitments among parties to the agreement to develop mechanisms for sharing information on pharmaceutical supply chain constraints and coordinate approaches with parties to minimize risks that could lead to supply chain failures; and (II) to the extent they have not done so yet, to obtain commitments from parties that they will fully implement the obligations under the World Trade Organization’s Agreement on Trade Facilitation prior to the date the agreement enters into force. (viii) With respect to enforcement— (I) to ensure that benefits under the agreement can only be obtained by parties that are fully meeting their obligations under the agreement